ArticleFrontiers in neurology2026
M2 macrophage-derived exosomes mitigate acute inflammation following ischemic stroke.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The acute inflammatory response following ischemic stroke is a key factor in exacerbating brain injury. Modulating excessive inflammation during the oxidative stress (OS) phase represents a potential therapeutic strategy; however, clinical interventions remain limited. Methods: M0 and M2 macrophage-derived exosomes (M0-exo and M2-exo) were administered to microglia under oxygen-glucose deprivation/reperfusion (OGD/R) conditions and to mice subjected to transient middle cerebral artery occlusion (tMCAO). The mechanisms underlying their anti-inflammatory effects were then investigated through a combination of bioinformatic analysis and fundamental experiments. Results: Treatment with exosomes markedly suppressed the expression of pro-inflammatory factors. Furthermore, they significantly reduced cerebral infarct volume and improved neurological function in mice. Notably, the anti-inflammatory effect of M2-exo was significantly superior to that of M0-exo. miRNA sequencing and subsequent validation revealed a specific enrichment of miR-330-5p in M2-exo. Mechanistic studies have demonstrated that miR-330-5p suppresses the expression of Spleen tyrosine kinase (Syk) and signal transducer and activator of transcription 3 (Stat3) in microglia, consequently reducing the production of downstream inflammatory factors. Treatment with Syk or Stat3 inhibitors partially mimicked the anti-inflammatory action of miR-330-5p in rescue studies. Conclusion: Our results unveil a novel anti-inflammatory pathway mediated by M2-exo, providing novel insights for stroke therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.